Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells
- 31 December 2003
- journal article
- review article
- Published by Elsevier BV in Seminars in Cancer Biology
- Vol. 13 (6), 461-472
- https://doi.org/10.1016/j.semcancer.2003.09.010
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cellsEuropean Journal of Immunology, 2002
- Biological and clinical developments in melanoma vaccinesExpert Opinion on Biological Therapy, 2001
- Enrichment and detection of live antigen-specific CD4+ and CD8+ T cells based on cytokine secretionEuropean Journal of Immunology, 1999
- A Phase I Trial of an HLA-A1 Restricted MAGE-3 Epitope Peptide with Incomplete Freundʼs Adjuvant in Patients with Resected High-Risk MelanomaJournal of Immunotherapy, 1999
- Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyte–defined Peptide Derived from the Tumor Antigen MAGE-3The Journal of Experimental Medicine, 1999
- Implications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunology Today, 1997
- Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory ReceptorImmunity, 1997
- Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.The Journal of Experimental Medicine, 1996
- Antigen-selected T-cell receptor diversity and self-nonself homologyImmunology Today, 1993
- A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.The Journal of Experimental Medicine, 1992